Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Laboratory support for transplantation

R W Yatscoff1

  • 1Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.

Clinical Chemistry
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined immunosuppression with cyclosporine, rapamycin, and mycophenolate mofetil controls rejection with minimal nutritional impact in experimental small intestinal transplantation.

Transplantation proceedings·2002
Same author

Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation.

Clinical therapeutics·2000
Same author

Minor immunophilin binding of tacrolimus and sirolimus metabolites.

Clinical biochemistry·2000
Same author

Comparison of steady-state trough sirolimus samples by HPLC and a radioreceptor assay.

Clinical biochemistry·2000
Same author

Pharmacokinetics and metabolism of sirolimus.

Therapeutic drug monitoring·2000
Same author

Current opinions on therapeutic drug monitoring of immunosuppressive drugs.

Clinical therapeutics·1999
Same journal

From Pooled Cohorts to PREVENT: A Perspective for Clinical Laboratorians.

Clinical chemistry·2026
Same journal

Interlaboratory Comparison of a Glucagon and Oxyntomodulin Immuno-LC-MS/MS Assay: Implications for Diabetes Research.

Clinical chemistry·2026
Same journal

Comparison of Information-Dependent Acquisition and Sequential Window Acquisition of All Theoretical Mass Spectra for Untargeted Drug Testing on a Linear Ion Trap-Pulsing Quadrupole-Time of Flight Mass Spectrometer.

Clinical chemistry·2026
Same journal

Patterns of One-Year Change in HbA1c and Continuous Glucose Monitoring (CGM) Metrics in Older Adults with Type 2 Diabetes.

Clinical chemistry·2026
Same journal

TSH Pediatric Reference Intervals: Lack of CALIPER Applicability to US-Based Populations.

Clinical chemistry·2026
Same journal

Rapid Detection of Hemoglobinopathy Variants Using One-Step Library Preparation and Nanopore Sequencing.

Clinical chemistry·2026
See all related articles

Clinical laboratories are crucial for transplantation, handling up to 35% of tests, including routine and specialized assays. New immunosuppressive drugs require updated therapeutic monitoring programs to support evolving transplant medicine.

Area of Science:

  • Clinical Laboratory Medicine
  • Transplantation Science

Background:

  • Clinical laboratories are integral to transplantation success.
  • Transplantation testing accounts for a significant portion of laboratory workload (up to 35%).
  • Testing includes both general laboratory procedures and transplantation-specific assays.

Purpose of the Study:

  • To highlight the critical role of clinical laboratories in supporting organ transplantation.
  • To address the growing need for specialized testing, particularly therapeutic drug monitoring, due to novel immunosuppressants.
  • To propose preliminary guidelines for monitoring new immunosuppressive drugs.

Main Methods:

  • Review of current laboratory testing practices in transplantation.
  • Analysis of the impact of new immunosuppressive drugs (e.g., FK506, cyclosporin G, rapamycin) on laboratory services.

Related Experiment Videos

  • Development of proposed monitoring guidelines.

    • Main Results:

    • Transplantation-specific tests include tissue typing, graft viability assessment, and drug level monitoring.
    • Emerging immunosuppressive drugs necessitate the development of new therapeutic monitoring programs.
    • Existing guidelines for cyclosporin A serve as a basis for new drug monitoring protocols.

    Conclusions:

    • Clinical laboratories face increasing demands to support complex transplant programs.
    • Adaptation of laboratory services is essential for managing new immunosuppressive therapies and potential xenotransplantation.
    • Standardized monitoring protocols are crucial for optimizing patient outcomes in transplantation.